Description

Bio-Rad Laboratories Faces Tariff Turmoil—Can Surcharges and Supply Shifts Save Margins? 

Bio-Rad Laboratories reported its financial performance for the first quarter of 2025, revealing mixed results influenced by both internal strategies and external economic factors. The company’s net sales for the quarter were approximately $585 million, representing a 4.2% decline from $611 million in the same period last year. On a currency-neutral basis, this reflected a 1.5% year-over-year decrease. This drop was primarily driven by lower sales within the Life Science segment, which faced softness due to reduced academic and biopharma research funding.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!